MaxCyte, Inc. (LON:MXCT – Get Free Report) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 0.98 and traded as high as GBX 1.17. MaxCyte shares last traded at GBX 1.14, with a volume of 563,557 shares.
MaxCyte Price Performance
The business’s fifty day simple moving average is GBX 0.99 and its 200-day simple moving average is GBX 1.07. The company has a current ratio of 12.39, a quick ratio of 14.38 and a debt-to-equity ratio of 9.70. The firm has a market cap of £1.29 million, a P/E ratio of -0.03 and a beta of 1.13.
About MaxCyte
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.
Further Reading
- Five stocks we like better than MaxCyte
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
- Beyond the AI Trade: 3 Defensive Stocks Built for Stability
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}